Melissa Palmer, MD

Liver disease consultant to pharmaceutical/biotech industry. Author of "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease." CEO of Liver Consulting LLC

[Melissa Palmer, MD @liverconsulting]

Excited to share this important publication (in press; will be on Pub Med in about a week) on GLP-1RA-associated #Hepatotoxicity that I was invited to write after I presented this topic, earlier this year, at an #AASLD online seminar.
https://t.co/LEYIEonOX4
#GLP-1 #semaglutide

[Melissa Palmer, MD @liverconsulting]

Only one more day to register for the online AASLD seminar on GLP-1RAs and Hepatotoxicity. January 15, at 11 AM ET. #semaglutide #liraglutide #DILI #Hepatology #drugdevelopment #MASH #obesity #Diabetes #liverinjury #liver
https://t.co/I0Inp0G6wQ

[Melissa Palmer, MD @liverconsulting]

Upcoming Online AASLD Seminar to be Presented by Melissa Palmer, MD

Please join me on January 15, 2026 at 11 AM Eastern Time for this online AASLD seminar on the topic of GLP-1RA and Hepatotoxicity.  Registration is now open via the link below.
https://t.co/L7YgM6fv8W

[Melissa Palmer, MD @liverconsulting]

On behalf of the Liver Forum, just published in AP&T -- https://t.co/O2OsicCHd5 . #liver #seladelpar #Ocaliva #MASH #NASH #MASLD #NAFLD #DILI #liverbiopsy #liverforum

[Melissa Palmer, MD @liverconsulting]

Please join me as I discuss how to detect, assess, and manage suspected DILI occurring during a clinical trial of patients with underlying liver disease #DILI #NASH #NAFLD #PSC #PBC #Biliaryatresia #BA #hepatology #ACLF #PFIC #Alagille #liverdisease #AASLD

[AASLD @AASLDtweets]

Join us for this upcoming Hepatotoxicity SIG Online Seminar Series!
Register online at https://t.co/VvfmZhppiH. #LiverTwitter

[Melissa Palmer, MD @liverconsulting]

Congratulations to @Pfizer for receiving FDA Fast Track Designation for Ervogastat/Clesacostat Combination Treatment for NASH.
But what does fast track actually mean?
https://t.co/eRmGgOQCWh
#NASH #liverdisease #FDA #drugdevelopment

[Melissa Palmer, MD @liverconsulting]

Didn’t have time to attend #DDW2022?
Here’s another interesting #Hepatology related presentation:

Title: The Trend of Novel #FDA Drugs and the Occurrence of #DILI from Jim Lewis’s group @MedStarHealth https://t.co/rqk5DVINR1
@DDWMeeting #liverdisease

[Melissa Palmer, MD @liverconsulting]

Didn't have time to attend DDW? Here's an interesting Hepatology-related presentation on the HepQuant's Disease Severity Index, along with my key takeaways https://t.co/d0j7ukXnez #NASH #Liverdisease #Hepatology

[Melissa Palmer, MD @liverconsulting]

I'd like to congratulate my co-authors on the publication of guidelines on detection of DILI during PBC and PSC clinical trials. #liver #hepatology #DILI #PBC #PSC https://t.co/PEzX79hw7y